Back to top

Image: Bigstock

Aerie Pharmaceuticals, Inc.

Read MoreHide Full Article

Aerie is positive on the efforts in developing its pipeline candidates. Aerie has filed a new drug application for its lead candidate, Rhopressa, in the U.S. in the Sep 2016 for treatment of glaucoma or ocular hypertension. A potential approval and successful commercialization of the drug will significantly boost the company’s growth prospects as glaucoma is one of the largest segments in the global ophthalmic market. We are also positive with Aerie’s second late-stage glaucoma candidate, Roclatan, which is being evaluated for lowering intraocular pressure in patients suffering from open-angle glaucoma and ocular hypertension. However, with no approved product in its portfolio, any regulatory setback would have an adverse impact on the stock. Estimates have remained mostly stable ahead of the company’s Q3 earnings release. However, the company has a negative record of earnings surprises in recent quarters.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Aerie Pharmaceuticals, Inc. (AERI) - free report >>

Published in